drugset / Trial / NCT00901615
Lenalidomide and R-CHOP in B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone).
Timeline
- Start
- 2009-01-06
- Primary completion
- 2010-11-19
- Completion
- 2015-11-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 2.5 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Vincristine | Small molecule | — | — |